Resources 
Product Resource
Learning
Worldwide Commercial Licensing Rights Secured：Jurkat E6.1, CHO-K1, HEK293, THP-1, Raji Cell Lines-Expanding Our Capabilities in Cell-Based Research.
ExploreArticles
Dectin-1 Cell Models for CLEC7A Signaling and Myeloid Cell Engager Research
Dectin-1 connects established antifungal biology with emerging research in AD neuroinflammation and myeloid cell engagers. Its context-dependent effects make fit-for-purpose in vitro models essential for interpreting candidate activity. Reqbio plans to expand its Dectin-1 and related myeloid-target cell model portfolio to support functional evaluation before animal studies. Reproducibility and mechanistic interpretation must be established for each intended use.
CD44v ADC Development: v6 & v9 Cell Models | Reqbio
With many ADC programs focused on the same targets, CD44v, a cancer stem cell marker, is attracting new interest. The CD44v9–xCT pathway is central to drug resistance, yet skin toxicity halted the development of a CD44v6-targeted ADC. This article discusses the biology of CD44v, lessons from drug development, and the practical research questions that Reqbio’s hCD44v6/CHO and hCD44v9/CHO cell models can help address. Contact us to discuss your research needs.
PDGFRA and PDGFRB Cell Models for Drug Discovery and Target Validation
PDGFRA and PDGFRB have a long history as drug-development targets. Their established biology can reduce mechanistic uncertainty, but the competitive landscape creates a high technical bar. Reliable tools remain important for data quality and batch consistency. When cell-based activity testing is part of a TKI release strategy, a well-characterized cell model is essential for generating consistent QC data. Reqbio developed this portfolio to provide coordinated tools for PDGFRA- and PDGFRB-focused drug development. The reporter cell models have been evaluated using ligands, receptor-blocking antibodies, and ligand-neutralizing antibodies to demonstrate the assay logic across these mechanisms.
Cell‑based Assay & Phenotypic Screening: Workflow, Advantages and CRO Service Solutions
Cell‑based assay occupies an irreplaceable position in modern preclinical drug discovery. It bridges the gap between molecular‑level biochemical experiments and in‑vivo animal studies. Selecting a qualified CRO partner with mature assay systems can greatly improve screening efficiency and data reliability. Contact our team to discuss your cell‑based screening project requirements.
MC2R: A Core GPCR of the HPA Axis and Cell Models for Drug Screening
As the terminal effector receptor of the HPA axis, MC2R is an essential regulator of cortisol and therefore a core target for drug development in endocrine disorders. The advancement of Atumelnant into Phase III clinical development marks the transition of this target from basic research to clinical translation. The MC2R CRE-Luc CHO cell model offered by Reqbio provides drug developers worldwide with a precise, flexible, and cross-validatable evaluation tool through its dual CRE-Luc reporter and HTRF cAMP assay modes.
IL-36/IL-36R: A Rising Star in the Treatment of Pustular Psoriasis and Broad-Spectrum Inflammatory Diseases
The IL-36/IL-36R axis is a central IL-1 superfamily pathway regulating inflammation in barrier tissues, and the successful approval of Spesolimab has validated its clinical druggability. The range of indications under investigation continues to expand, from GPP and hidradenitis suppurativa to palmoplantar pustulosis and inflammatory bowel disease. With pathway-specific design, flexible experimental formats, and blocking validation, Reqbio's adherent and suspension IL-36 effector reporter cell models provide drug developers worldwide with reliable and efficient evaluation tools.
info@reqbio.com
